VirtualScopics Reports First Quarter 2013 Results Awards and Bookings Advance 40% over Year to Date 2012 PR Newswire ROCHESTER, N.Y., May 15, 2013 ROCHESTER, N.Y., May 15, 2013 /PRNewswire/ --VirtualScopics, Inc. (NASDAQ:VSCP), a leading provider of quantitative imaging, today announced revenues of $2,532,587 for the quarter ended March 31, 2013 compared to $3,702,159 for the quarter ended March 31, 2012. Net loss for the three months ended March 31, 2013 was $1,112,948 compared to a net loss of $613,544 for the three months ended March 31, 2012. Other first quarter ended March 31, 2013 results were: oGross margin of 31% compared to 38% in the first quarter of 2012. oOperating loss of $1,117,456 compared to an operating loss of $218,780 in the first quarter of 2012. Excluding investments made in personalized medicine, operating loss of $772,898 in the first quarter of 2013. oAdjusted EBITDA of ($880,356) compared to $82,106 for the first quarter of 2012. Excluding investments made in personalized medicine, Adjusted EBITDA of ($535,798) in the first quarter of 2013. Jeff Markin, president and chief executive officer of VirtualScopics stated, "While our revenues continue to suffer due to our low new project bookings in 2012 we are encouraged with our sales performance this year." He added, "Included in year to date project awards is the analysis of a significant Phase III study that will occur primarily in the second quarter. This project, along with others awarded to date, demonstrates a greater than 40% increase in awards and bookings over the same period in 2012." He continued, "While our softness in 2012 bookings will continue to impact near term revenue we are optimistic that the measures we put in place last year are now showing increased sales activity." He further stated, "Another example of our improving sales efforts is seen in the number of individual project awards in the first quarter of 2013 which has doubled versus those won during the same period of 2012. Additionally, over the last two quarters we were awarded more projects during a two-quarter period than at any time over the past two years." He concluded, "We believe this sales momentum will continue as the year progresses." "In light of the continued softness in our top line, we remain diligent in monitoring our costs," stated Molly Henderson, chief business and financial officer of VirtualScopics. She added, "Although the analysis of the Phase III study is occurring later than we anticipated, we are confident in our ability to meet the condensed timeline and that we will see a positive impact to second quarter results." She continued, "In addition to the increase in the number of project awards in 2013 we are encouraged by the nature of the new business we have experienced." She further added, "Of note, seven of our year to date 2013 project awards came from new customers. This number exceeds the amount of new customers we secured in all of 2012." She stated, "Incoming requests for proposal (RFPs) remain strong as we received a greater number during the first quarter of 2013 than any previous first quarter in the company's history, which gives us confidence on the health of the industry and the interest in our services." She concluded, "While we are optimistic in our ability to translate these RFPs into awarded projects, we believe it's critical for us to ensure our cost structure is in line with our opportunities in order to minimize the amount of cash consumed during these times of fluctuating revenue." Jeff Markin and Molly Henderson will provide a business update and discuss these results during the conference call today at 11:00 a.m. ET. Interested participants should call 877-407-8035 when calling within the United States or +1 201 689 8035 when calling internationally. This call can also be accessed at www.virtualscopics.com and will be available for 30 days after the call. The Company provides Adjusted EBITDA as a supplemental measure to Generally Accepted Accounting Principles ("GAAP") regarding the Company's operational performance. The Company defines Adjusted EBITDA as earnings less interest, taxes (if any), depreciation and amortization as further adjusted to exclude stock-based compensation expense and the loss/gain on derivative liabilities (mark to market adjustment for warrants). This financial measure excludes the impact of certain items and, therefore, has not been calculated in accordance with GAAP. The Company's method of calculating Adjusted EBITDA, however, may differ from methods used by other companies, and, as a result, Adjusted EBITDA measures disclosed herein may not be comparable to other similarly titled measures used by other companies. The Company continues to provide information in accordance with GAAP, however, with the adoption of Accounting Standards Codification ("ASC") 815-40 and the non-cash variable nature of stock-based compensation expense and their very substantial impact on the overall reported net income/loss, the Company believes it is also helpful for investors to receive additional information relating more specifically to the Company's operating results. Accordingly, the Company has presented Adjusted EBITDA which excludes the non-cash effects of ASC 815-40 and ASC 718 on its financial results. Management uses Adjusted EBITDA (a) to evaluate the Company's financial performance, (b) to set internal spending budgets, and (c) to measure operational profitability. In addition, investors have requested these non-GAAP financial measures as a means of providing consistent and comparable information with past reports of financial results. Pursuant to the requirements of Regulation G, the Company has provided a reconciliation of Adjusted EBITDA to the most directly comparable GAAP financial measure, net income/(loss), below. About VirtualScopics, Inc. VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit www.virtualscopics.com. Forward-Looking Statements The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company's investment in infrastructure and new customer contract signings and awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov. These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to contact awards, the risk that they may not get signed. Other risks include the company's dependence on its largest customers and risks of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements. -Financial tables to follow- CONTACTS: Investor Relations: Company Contact: Tim Ryan Molly Henderson Chief Business The Shoreham Group and Financial Officer, Sr. Vice President 80 Eighth Ave, Ste 1107 500 Linden Oaks New York, NY 10011 Rochester, New York 14625 +1 212 242 7777 Direct +1 585 249.6231 firstname.lastname@example.org VirtualScopics, Inc. and Subsidiary Condensed Consolidated Statements of Operations (unaudited) For the Three Months Ended March 31, 2013 2012 Revenues $ $ 2,282,831 3,293,659 Reimbursement revenues 249,756 408,500 Total revenues 2,532,587 3,702,159 Cost of revenues 1,497,539 1,882,745 Cost of reimbursement revenues 249,756 408,500 Total cost of services 1,747,295 2,291,245 Gross profit 785,292 1,410,914 Operating expenses Research and development 433,846 356,326 Sales and marketing 354,609 331,072 General and administrative 890,035 654,741 Stock-based compensation expense 127,945 175,936 Depreciation and amortization 96,313 111,619 Total operating 1,902,748 1,629,694 expenses Operating loss (1,117,456) (218,780) Other income (expense) Interest income 1,010 416 Other expense (1,372) (268) Unrealized gain (loss) on change in 4,870 (394,912) fair value of derivative liabilities Total other income (expense) 4,508 (394,764) Net loss (1,112,948) (613,544) Preferred stock dividends 42,000 12,000 Net loss available to common $ $ stockholders (1,154,948) (625,544) Basic and diluted net loss per common $ $ share (0.04) (0.02) Weighted average number of common shares outstanding basic and diluted 29,799,523 29,370,687 * Cost of revenues includes non-cash stock-based compensation expense of $12,842 and $13,331 for the three months ended March 31, 2013 and 2012, respectively. VirtualScopics, Inc. and Subsidiary Condensed Consolidated Balance Sheets March 31, December 31, 2013 2012 Assets (unaudited) Current assets Cash $ 7,265,060 $ 8,523,807 Accounts receivable, net 2,168,984 1,762,507 Prepaid expenses and other current assets 460,116 437,698 Total current assets 9,894,160 10,724,012 Patents, net 1,428,511 1,470,436 Property and equipment, net 360,416 399,569 Other assets - 5,428 Total assets $ 11,683,087 $ 12,599,445 Liabilities and Stockholders' Equity Current liabilities Accounts payable and accrued expenses $ 991,762 $ 856,702 Accrued payroll 431,484 481,661 Unearned revenue 248,299 272,509 Dividends payable 167,333 125,333 Derivative liabilities 11,080 15,950 Total current liabilities 1,849,958 1,752,155 Commitments and Contingencies - - Stockholders' Equity Convertible preferred stock, $0.001 par value; 15,000,000 shares authorized; Series C-1; 3,000 shares authorized; issued and outstanding, 3,000 at March 31, 2013 and December 31, 2012; 3 3 liquidation preference $1,000 per share Series B 6,000 shares authorized; issued and outstanding, 600 at March 31, 1 1 2013 and December 31, 2012; liquidation preference $1,000 per share Series A 8,400 shares authorized; issued and outstanding, 2,190 at March 2 2 31, 2013 and December 31, 2012; liquidation preference $1,000 per share Series C-2 3,000 shares authorized; none issued and outstanding, at March - - 31, 2013 and December 31, 2012; liquidation preference $1,000 per share Common Stock, $0.001 par value; 85,000,000 shares authorized; issued 29,958,795 and 29,799,523 shares at March 31, 2013 and December 31, 29,800 29,800 2012, respectively; outstanding, 29,799,523 shares at March 31, 2013 and December 31, 2012, respectively Additional paid-in capital 21,879,871 21,781,084 Accumulated deficit (12,076,548) (10,963,600) Total stockholders' equity 9,833,129 10,847,290 Total liabilities and stockholders' equity $ 11,683,087 $ 12,599,445 Three Months Ended Three Months Ended Adjusted EBITDA (non-GAAP March 31, 2013 March 31, 2012 measurement): (unaudited) (unaudited) Net loss $ $ (1,112,948) (613,544) Interest income and other 362 (148) expenses Depreciation and amortization 96,313 111,619 Stock-based compensation 140,787 189,267 expense Unrealized (gain) loss on change in fair value of (4,870) 394,912 derivative liabilities Adjusted EBITDA $ $ (880,356) 82,106 Basic and diluted Adjusted $ $ EBITDA per common share, (0.03) 0.00 non-GAAP SOURCE VirtualScopics, Inc. Website: http://www.virtualscopics.com
Swiss National Bank Introduces Negative Interest Rate of -0.25%
VirtualScopics Reports First Quarter 2013 Results
Press spacebar to pause and continue. Press esc to stop.